CLRB
Price
$1.17
Change
-$0.11 (-8.59%)
Updated
Oct 22 closing price
Capitalization
11.06M
20 days until earnings call
Intraday BUY SELL Signals
QTTB
Price
$8.80
Change
+$0.13 (+1.50%)
Updated
Oct 22 closing price
Capitalization
261.97M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLRB vs QTTB

CLRB vs QTTB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CLRB vs. QTTB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRB is a Hold and QTTB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CLRB with price predictions
Oct 22, 2026

Momentum Indicator for CLRB turns negative, indicating new downward trend

CLRB saw its Momentum Indicator move below the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CLRB turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for CLRB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for CLRB's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in 184 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CLRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.370) is normal, around the industry mean (2.973). P/E Ratio (-0.529) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for QTTB with price predictions
Oct 22, 2026

QTTB's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for QTTB turned positive on October 08, 2026. Looking at past instances where QTTB's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on QTTB as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 212 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for QTTB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.474) is normal, around the industry mean (2.973). P/E Ratio (2.803) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CLRB vs QTTB: Fundamental Ratings
CLRB
QTTB
OUTLOOK RATING
1..100
564
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
9916
PRICE GROWTH RATING
1..100
9341
P/E GROWTH RATING
1..100
823
SEASONALITY SCORE
1..100
8590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (46) in the Biotechnology industry is in the same range as QTTB (76) in the null industry. This means that CLRB’s stock grew similarly to QTTB’s over the last 12 months.

QTTB's Profit vs Risk Rating (99) in the null industry is in the same range as CLRB (100) in the Biotechnology industry. This means that QTTB’s stock grew similarly to CLRB’s over the last 12 months.

QTTB's SMR Rating (16) in the null industry is significantly better than the same rating for CLRB (99) in the Biotechnology industry. This means that QTTB’s stock grew significantly faster than CLRB’s over the last 12 months.

QTTB's Price Growth Rating (41) in the null industry is somewhat better than the same rating for CLRB (93) in the Biotechnology industry. This means that QTTB’s stock grew somewhat faster than CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (8) in the Biotechnology industry is in the same range as QTTB (23) in the null industry. This means that CLRB’s stock grew similarly to QTTB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLRBQTTB
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CLRB: $1.17 vs. QTTB: $8.80)
Brand notoriety: CLRB and QTTB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRB: 72% vs. QTTB: 38%
Market capitalization -- CLRB: $11.06M vs. QTTB: $261.97M
CLRB [@Biotechnology] is valued at $11.06M. QTTB’s [@Biotechnology] market capitalization is $261.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRB’s FA Score shows that 1 FA rating(s) are green while QTTB’s FA Score has 2 green FA rating(s).

  • CLRB’s FA Score: 1 green, 4 red.
  • QTTB’s FA Score: 2 green, 3 red.
According to our system of comparison, QTTB is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRB’s TA Score shows that 4 TA indicator(s) are bullish while QTTB’s TA Score has 5 bullish TA indicator(s).

  • CLRB’s TA Score: 4 bullish, 4 bearish.
  • QTTB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, QTTB is a better buy in the short-term than CLRB.

Price Growth

CLRB (@Biotechnology) experienced а -1.68% price change this week, while QTTB (@Biotechnology) price change was +13.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

CLRB is expected to report earnings on Nov 12, 2026.

QTTB is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CLRB
Daily Signal:
Gain/Loss:
QTTB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-8.59%
QTTB - CLRB
62%
Loosely correlated
+1.50%
ADCT - CLRB
43%
Loosely correlated
+6.67%
RKTO - CLRB
42%
Loosely correlated
+1.39%
OGEN - CLRB
41%
Loosely correlated
-1.82%
ANAB - CLRB
40%
Loosely correlated
+0.33%
More

QTTB and

Correlation & Price change

A.I.dvisor indicates that over the last year, QTTB has been loosely correlated with CLRB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if QTTB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QTTB
1D Price
Change %
QTTB100%
+1.50%
CLRB - QTTB
62%
Loosely correlated
-8.59%
MESO - QTTB
51%
Loosely correlated
-2.18%
STOK - QTTB
49%
Loosely correlated
+0.08%
IBRX - QTTB
40%
Loosely correlated
-3.82%
ANAB - QTTB
39%
Loosely correlated
+0.33%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HPQ33.762.44
+7.79%
HP
ALXO1.190.04
+3.48%
ALX Oncology Holdings
GDTC0.920.02
+1.72%
CytoMed Therapeutics Limited
HP37.13-1.12
-2.93%
Helmerich & Payne
CEVA28.20-1.58
-5.31%
CEVA